Litigation Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Docket		Date Filed	2023-02-10
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	Plaintiff	Referred To
Patents	10,071,977; 10,149,829; 10,376,487; 11,285,129; 11,918,556; 8,785,492; 9,730,910; RE46,604
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-10				External link to document
2023-02-10	47	Opinion	, 2018) (adding U.S. Patent No. 10,071,977); see Def. Br. at 5 (noting 15 patents asserted in total). …5. Vanda holds multiple patents relating to tasimelteon. The suit for patent infringement underlying …motion to transfer concerns U.S. Patent No. 11,285,129 (the ’129 patent), which issued on March 29, 2022…related patents. 2 See Compl. ¶¶ 22-39, Vanda Pharms. 2 Vanda originally asserted six patents but added…later-issued patents to the Delaware litigation, Vanda would not assert any additional patents against Teva	External link to document
2023-02-10	78	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious as a …Litigation Involving Related Patents Before asserting the ’129 patent here, Vanda previously sued…the ’829 patent”), both of which are related to the ’129 patent and share a common specification. Following…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. See Vanda Pharm	External link to document
2023-02-10	91	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious based…“the ’829 patent”), which are related to the ’129 patent and share a specification. Following a four-…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. Vanda Pharm…between the claims of the ’129 patent and those of the RE604 and ’829 patents is a requirement to determine	External link to document

Vanda Pharmaceuticals v. Apotex: Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: September 26, 2026

Vanda Pharmaceuticals sued Apotex in the U.S. District Court for the District of Delaware after Apotex filed an abbreviated new drug application seeking approval for a generic version of Hetlioz (tasimelteon). The case, No. 1:23-cv-00153, is a Hatch-Waxman patent action focused on Vanda’s method-of-use and related patent rights for tasimelteon. The principal commercial issue is whether Apotex can launch before the expiration of Vanda’s asserted patents or obtain a court ruling of invalidity or non-infringement.

What drug and product are at issue in Vanda Pharmaceuticals v. Apotex?

The dispute concerns Hetlioz, the commercial product containing tasimelteon, a melatonin-receptor agonist marketed by Vanda.

Item	Details
Brand	Hetlioz
Active ingredient	Tasimelteon
Sponsor	Vanda Pharmaceuticals Inc.
FDA product	Hetlioz capsules
Primary indication	Non-24-hour sleep-wake disorder
Regulatory pathway	Abbreviated New Drug Application filed by Apotex
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:23-cv-00153
Filed	February 8, 2023
Case type	Hatch-Waxman patent infringement action

The case is separate from disputes involving Vanda’s other products, including Fanapt (iloperidone). The relevant commercial product in this action is tasimelteon.

What patents protect Hetlioz and tasimelteon?

Vanda’s Hetlioz patent estate has included patents directed to tasimelteon treatment methods, circadian-rhythm disorders, dosing, and related therapeutic applications. The patents asserted against Apotex are identified in Vanda’s complaint and associated patent disclosures.

Representative Vanda tasimelteon patents include:

Patent	General subject matter	Business relevance
U.S. Patent No. 8,586,610	Treatment of circadian-rhythm disorders with tasimelteon	Core method-of-use protection
U.S. Patent No. 9,730,834	Tasimelteon treatment methods	Later-issued method claims
U.S. Patent No. 10,098,879	Treatment of sleep and circadian-rhythm disorders	Potential Orange Book and litigation barrier
U.S. Patent No. 10,143,693	Tasimelteon therapeutic methods	Method-of-use protection
U.S. Patent No. 10,238,656	Additional tasimelteon treatment claims	Later patent-layer protection

The exact patent claims in issue depend on the patents listed in Vanda’s complaint and the certifications submitted in Apotex’s ANDA. Hatch-Waxman litigation generally turns on whether the proposed generic product would infringe the asserted claims if marketed according to the ANDA labeling.

What formulations are protected by Vanda’s patents?

The primary protection in the Vanda-Apotex dispute is method-of-use protection rather than a simple composition-of-matter patent. That distinction matters because a generic applicant may attempt to avoid infringement through a Section viii statement or a restricted label that omits patented indications.

For tasimelteon, the relevant patent barriers may include:

• Treatment of Non-24-hour sleep-wake disorder.
• Administration of tasimelteon at specified doses or times.
• Use in patient populations with particular circadian-rhythm characteristics.
• Therapeutic methods tied to the Hetlioz label.
• Potential claims covering pediatric or other approved uses, depending on the asserted patent set.

The commercial value of each patent depends on whether the FDA-approved generic label would necessarily practice the claim. A patent with claims closely aligned to the approved label is more difficult to design around than a patent covering an optional use.

What triggered the Vanda Pharmaceuticals v. Apotex lawsuit?

Apotex filed an ANDA seeking FDA approval for a generic tasimelteon product. Vanda then filed the Delaware action under the Hatch-Waxman framework.

An ANDA applicant must address listed patents for the reference drug through one of four certifications:

1. Paragraph I: No patent information has been submitted.
2. Paragraph II: The listed patent has expired.
3. Paragraph III: The applicant will not market the drug until patent expiration.
4. Paragraph IV: The listed patent is invalid, unenforceable, or will not be infringed.

Vanda’s lawsuit indicates that Apotex made a certification or filing position that created a statutory basis for patent litigation. The suit triggered the Hatch-Waxman 30-month stay, subject to statutory exceptions and any court order affecting the stay.

What is the Orange Book status of Hetlioz?

Hetlioz patents are evaluated through FDA Orange Book listings. Orange Book-listed patents can delay approval of an ANDA when the brand company sues within the statutory period following notice of a Paragraph IV certification.

The regulatory significance is as follows:

Regulatory event	Effect
Orange Book patent listing	Requires the ANDA applicant to make a patent certification
Paragraph IV notice	Gives the innovator a basis to sue for patent infringement
Timely patent suit	Generally triggers a 30-month stay of final FDA approval
Patent expiration	Removes the relevant patent-based approval barrier
Court ruling for generic	May permit approval before the listed patent expires
Court ruling for Vanda	Can delay approval until expiration or claim invalidation

FDA approval and commercial launch are separate issues. A generic may receive approval but remain subject to a court injunction, a settlement restriction, pediatric exclusivity, or another regulatory limitation.

When does Hetlioz lose exclusivity?

Hetlioz exclusivity has several components:

• Regulatory exclusivity attached to the original FDA approval.
• Patent protection for tasimelteon treatment methods.
• Any pediatric exclusivity period.
• Patent-term adjustments or other extensions.
• The 30-month stay associated with Apotex’s ANDA litigation.

The earliest relevant generic-entry date is controlled by the shortest effective barrier that remains enforceable. The practical date may be later than a patent’s nominal expiration if Vanda secures an injunction or settles with launch restrictions.

The patent estate includes patents with expiration dates extending beyond the earliest composition and basic method patents. Later-issued method patents can preserve protection even after earlier patents expire, provided the relevant claims survive validity and infringement challenges.

What legal issues will determine the outcome?

Infringement

Vanda must show that Apotex’s proposed product or labeling would infringe at least one asserted patent claim. For method-of-use patents, the central issue is usually whether the ANDA label directs or encourages use in the patented manner.

Apotex may argue that:

• Its proposed label does not require a patented use.
• The label omits the relevant indication.
• Physicians or patients would not be directed toward the claimed method.
• The generic product can be used for non-infringing purposes.
• The ANDA product does not satisfy one or more claim limitations.

Vanda may respond that the proposed labeling, dosing instructions, clinical information, and intended use establish induced infringement.

Validity

Apotex can challenge patent validity based on:

• Anticipation.
• Obviousness.
• Lack of written description.
• Lack of enablement.
• Indefiniteness.
• Patent-term or statutory defects.

Tasimelteon litigation may present obviousness issues involving prior art on melatonin receptors, circadian-rhythm disorders, sleep-wake disorders, dose selection, and clinical trial results.

Enforceability

Apotex could also raise inequitable conduct or other enforceability defenses if supported by the prosecution record. These defenses generally require a stronger factual showing than a standard invalidity defense.

Claim construction

The court may need to construe terms concerning:

• Circadian-rhythm disorders.
• Non-24-hour sleep-wake disorder.
• Timing of administration.
• Patient selection.
• Sleep onset or sleep maintenance.
• Required therapeutic effects.

Claim construction can determine whether the patents cover Apotex’s proposed label before the case reaches a full trial.

What is the litigation status?

The case is a Delaware Hatch-Waxman action filed by Vanda against Apotex in February 2023. The litigation was initiated to prevent or delay approval and commercial marketing of Apotex’s generic tasimelteon product based on Vanda’s asserted patents.

The principal procedural milestones in a case of this type are:

Stage	Significance
Complaint filed	Begins the patent action and invokes Hatch-Waxman remedies
ANDA certification disclosed	Defines the patent disputes
Answer and counterclaims	Apotex typically challenges validity, enforceability, and infringement
Fact discovery	Parties exchange technical, regulatory, and prosecution evidence
Claim construction	Court interprets disputed patent terms
Summary judgment	Court may resolve infringement or validity issues before trial
Bench trial	Delaware patent cases are tried to the court
Final judgment	Determines whether approval or launch is blocked
Appeal	Federal Circuit review may extend uncertainty

No settlement, final judgment, or commercial launch should be presumed solely from the case number. A definitive launch date requires review of the latest docket entries, FDA approval status, patent expiration data, and any confidential or publicly filed settlement terms.

Are there Paragraph IV challenges against Hetlioz?

The Vanda-Apotex case is consistent with a Paragraph IV-driven Hatch-Waxman dispute. A Paragraph IV certification contests one or more Orange Book-listed patents by asserting that the patent is invalid, unenforceable, or not infringed.

Paragraph IV litigation creates two separate risks for Vanda:

1. Apotex may obtain an early court ruling allowing FDA approval and launch.
2. Apotex may reach a settlement permitting a negotiated launch date before full patent expiration.

The commercial impact depends on the number of other ANDA applicants. Multiple Paragraph IV filers can reduce Vanda’s ability to preserve a high-value settlement structure because the first challenger may not control the entire generic-entry timetable.

Which companies are challenging Hetlioz?

The supplied case identifies Apotex as a challenger. Generic competition for tasimelteon may also involve other ANDA applicants, but each challenger must be analyzed separately because:

• The asserted patents may differ.
• The certification dates may differ.
• The first-filer position may differ.
• Settlements may contain different launch dates.
• An applicant may use a Section viii statement rather than a Paragraph IV certification.
• FDA approval may occur at different times.

A complete market forecast therefore requires a consolidated ANDA and litigation map, not analysis of the Apotex case alone.

How strong is Vanda’s tasimelteon patent estate?

Vanda’s estate has meaningful defensive value because it uses multiple patent layers rather than relying exclusively on one early composition patent. The estate’s strength is mixed:

Strength factor	Assessment
Multiple issued patents	Supports layered enforcement
Method-of-use coverage	Can align directly with the approved label
Later-issued patents	May extend the practical barrier beyond earlier patents
Composition protection	Less central if early composition patents have expired
Design-around risk	Material if Apotex can omit patented indications
Validity risk	Depends on prior art and claim scope
Regulatory leverage	Orange Book listings can delay final approval
Litigation leverage	Strongest where the generic label directly practices the claims

The estate is stronger against a full-label generic than against a carefully restricted product. The main vulnerability is that method-of-use claims can be difficult to enforce when the generic applicant proposes a label that omits or narrows the patented indication.

What generic launch scenarios exist for Apotex?

Scenario 1: Vanda wins on infringement and validity

Apotex would be blocked from commercial launch until the relevant patent barriers expire, unless it obtains appellate relief or reaches a later settlement.

Scenario 2: Apotex wins on non-infringement

FDA approval could proceed after removal of the litigation stay, subject to all remaining patents and regulatory requirements. This is the most disruptive outcome for Vanda because it could permit entry before the expected patent-protected period ends.

Scenario 3: Apotex invalidates key patents

Invalidation of broad or label-linked patents could open the market to Apotex and increase pressure from other ANDA applicants.

Scenario 4: Settlement

A settlement could provide Apotex with a negotiated launch date, potentially before the last asserted patent expiration. The value of the settlement depends on the date, whether it includes authorized-generic restrictions, and whether other challengers remain active.

Scenario 5: Skinny-label entry

Apotex could seek approval for non-patented uses while omitting patented indications. This would reduce infringement exposure but may limit the product’s commercial addressable market.

What is the revenue exposure for Vanda?

Hetlioz is a key commercial product for Vanda, and generic entry would likely affect:

• Net sales and gross margin.
• Pricing power.
• Payor rebates.
• Prescriber retention.
• Patient switching.
• Sales-force economics.
• Valuation of Vanda’s remaining pipeline.

The revenue impact would not necessarily equal an immediate 100% loss of Hetlioz sales. Early erosion depends on the number of entrants, generic pricing, substitution rules, pharmacy benefit design, formulation equivalence, and the scope of the approved generic label.

A single generic entrant can produce substantial price pressure. Multiple entrants generally accelerate erosion. A restricted-label launch may have a smaller initial effect but can expand if physicians prescribe the generic broadly or if later litigation removes labeling constraints.

How does the Apotex dispute compare with biosimilar litigation?

This is a small-molecule ANDA case, not a biologic biosimilar case.

Issue	Hetlioz-Apotex	Biosimilar litigation
FDA pathway	ANDA under Hatch-Waxman	BLA and Biologics Price Competition and Innovation Act
Product type	Small molecule	Biologic
Patent disclosure	Orange Book	Patent dance and related disclosures
Key challenge	Paragraph IV certification	BPCIA patent litigation
Interchangeability	Not generally the central issue	May affect pharmacy substitution
Manufacturing complexity	Lower than biologics, but still relevant	Often a major barrier
Launch mechanics	30-month stay may apply	Different statutory timing rules

Manufacturing know-how may still matter for tasimelteon, but the key obstacle in this case is patent and regulatory timing rather than biosimilar interchangeability.

What manufacturing and geographic risks remain?

The U.S. litigation affects FDA approval and U.S. commercialization. It does not automatically determine rights in Europe, Canada, Japan, or other markets.

Vanda’s risk profile by region depends on:

• National patent filings.
• Patent-term adjustments.
• Supplementary protection certificates outside the United States.
• Local regulatory exclusivity.
• National generic approval pathways.
• Local infringement proceedings.
• Manufacturing and supply arrangements.

Apotex’s ability to launch in the United States does not establish freedom to operate in other jurisdictions. Conversely, foreign-market entry would not resolve the U.S. case.

Key Takeaways

• Vanda sued Apotex in Delaware over an ANDA for generic tasimelteon, the active ingredient in Hetlioz.
• The dispute is a Hatch-Waxman case centered on Vanda’s tasimelteon patent estate.
• Method-of-use patents are likely to be more important than an unexpired composition patent.
• Apotex’s principal defenses are expected to include non-infringement, invalidity, and possible label-based design-around arguments.
• The 30-month stay and any final injunction depend on the asserted patents and the procedural posture of the case.
• A settlement could establish a negotiated generic-entry date without a final merits ruling.
• The financial exposure is tied to the timing, number, and commercial scope of generic entrants.
• The case does not involve biosimilar regulation; it follows the small-molecule ANDA pathway.

FAQs About Vanda Pharmaceuticals v. Apotex

What is Civil Action No. 1:23-cv-00153?

It is Vanda Pharmaceuticals Inc. v. Apotex Inc., a U.S. District Court for the District of Delaware patent action concerning Apotex’s proposed generic tasimelteon product.

Is Apotex allowed to sell generic Hetlioz now?

Commercial launch depends on FDA approval, the status of the 30-month stay, asserted patent expiration, court orders, and any settlement terms. The civil action itself does not establish launch authorization.

Does this case concern Fanapt?

No. The product at issue is Hetlioz, which contains tasimelteon. Fanapt contains iloperidone and is associated with separate Vanda patent and regulatory issues.

Can a generic launch with a label that omits patented indications?

Potentially. A Section viii strategy or a restricted label can reduce infringement risk, but the outcome depends on the patent claims, FDA-approved labeling, and whether the proposed labeling induces infringement.

What would invalidate Vanda’s Hetlioz patent protection?

A final court ruling could invalidate claims for anticipation, obviousness, lack of enablement, inadequate written description, indefiniteness, or another statutory defect. A finding of non-infringement could also remove the practical barrier without invalidating the patents.

References

1. U.S. District Court for the District of Delaware. (2023). Vanda Pharmaceuticals Inc. v. Apotex Inc., No. 1:23-cv-00153, complaint and docket materials.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2022). Abbreviated new drug application approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

5. Vanda Pharmaceuticals Inc. (n.d.). Hetlioz prescribing information. Vanda Pharmaceuticals Inc.